(Q28305304)

2

0 references

N Isoherranen

3

0 references

C Hoffer

4

0 references

P Sheffels

5

0 references

K Thummel

6

0 references

D Whittington

7

0 references

D Ensign

Clinical Pharmacology & Therapeutics

8

0 references

language of work or name

English

0 references

publication date

October 2007

0 references

published in

0 references

volume

82

0 references

issue

4

0 references

page(s)

410-26

0 references

cites work

Drug metabolism and variability among patients in drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

The human intestinal cytochrome P450 "pie".

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Clinical implications of CYP3A polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Noninvasive tests of CYP3A enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Genetic variability in CYP3A5 and its possible consequences.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Significance of the minor cytochrome P450 3A isoforms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

The influence of age and sex on the clearance of cytochrome P450 3A substrates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Midazolam is metabolized by at least three different cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Comparative pharmacokinetics of fentanyl and alfentanil.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Cytochrome P450 3A polymorphisms and immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 genetic polymorphisms in different ethnic populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Ethnic differences in the distribution of CYP3A5 gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021

Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100237

7 January 2021